Literature DB >> 22310854

[68Ga]Gallium-labelled PSMA ligand as superior PET tracer for the diagnosis of prostate cancer: comparison with 18F-FECH.

A Afshar-Oromieh1, U Haberkorn, M Eder, M Eisenhut, C M Zechmann.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22310854     DOI： 10.1007/s00259-012-2069-0

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN： 1619-7070            Impact factor:   9.236


× No keyword cloud information.
  5 in total

1.  68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging.

Authors:  Matthias Eder; Martin Schäfer; Ulrike Bauder-Wüst; William-Edmund Hull; Carmen Wängler; Walter Mier; Uwe Haberkorn; Michael Eisenhut
Journal:  Bioconjug Chem       Date:  2012-03-13       Impact factor: 4.774

2.  Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature.

Authors:  S S Chang; V E Reuter; W D Heston; N H Bander; L S Grauer; P B Gaudin
Journal:  Cancer Res       Date:  1999-07-01       Impact factor: 12.701

3.  Prostate-specific membrane antigen is produced in tumor-associated neovasculature.

Authors:  S S Chang; D S O'Keefe; D J Bacich; V E Reuter; W D Heston; P B Gaudin
Journal:  Clin Cancer Res       Date:  1999-10       Impact factor: 12.531

4.  Preclinical evaluation of novel glutamate-urea-lysine analogues that target prostate-specific membrane antigen as molecular imaging pharmaceuticals for prostate cancer.

Authors:  Shawn M Hillier; Kevin P Maresca; Frank J Femia; John C Marquis; Catherine A Foss; Nghi Nguyen; Craig N Zimmerman; John A Barrett; William C Eckelman; Martin G Pomper; John L Joyal; John W Babich
Journal:  Cancer Res       Date:  2009-08-25       Impact factor: 12.701

Review 5.  Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer.

Authors:  Arundhati Ghosh; Warren D W Heston
Journal:  J Cell Biochem       Date:  2004-02-15       Impact factor: 4.429
  5 in total
  99 in total

1.  Comparison of hybrid 68Ga-PSMA-PET/CT and 99mTc-DPD-SPECT/CT for the detection of bone metastases in prostate cancer patients: Additional value of morphologic information from low dose CT.

Authors:  Jan-Carlo Janssen; Sebastian Meißner; Nadine Woythal; Vikas Prasad; Winfried Brenner; Gerd Diederichs; Bernd Hamm; Marcus R Makowski
Journal:  Eur Radiol       Date:  2017-08-04       Impact factor: 5.315

2.  [(18)F]Fluorobenzoyllysinepentanedioic Acid Carbamates: New Scaffolds for Positron Emission Tomography (PET) Imaging of Prostate-Specific Membrane Antigen (PSMA).

Authors:  Xing Yang; Ronnie C Mease; Mrudula Pullambhatla; Ala Lisok; Ying Chen; Catherine A Foss; Yuchuan Wang; Hassan Shallal; Hannah Edelman; Adam T Hoye; Giorgio Attardo; Sridhar Nimmagadda; Martin G Pomper
Journal:  J Med Chem       Date:  2015-12-16       Impact factor: 7.446

3.  PET/MRI with a 68Ga-PSMA ligand for the detection of prostate cancer.

Authors:  Ali Afshar-Oromieh; Uwe Haberkorn; Boris Hadaschik; Gregor Habl; Matthias Eder; Michael Eisenhut; Heinz-Peter Schlemmer; Matthias C Roethke
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-07-02       Impact factor: 9.236

4.  Writing PET into existence.

Authors:  A Chiti; M Kirienko; E Incerti; M Picchio
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-09-27       Impact factor: 9.236

Review 5.  Current use of PSMA-PET in prostate cancer management.

Authors:  Tobias Maurer; Matthias Eiber; Markus Schwaiger; Jürgen E Gschwend
Journal:  Nat Rev Urol       Date:  2016-02-23       Impact factor: 14.432

Review 6.  68Ga-DOTA and analogs: Current status and future perspectives.

Authors:  Krzysztof Kilian
Journal:  Rep Pract Oncol Radiother       Date:  2014-05-19

7.  Effects of arm truncation on the appearance of the halo artifact in 68Ga-PSMA-11 (HBED-CC) PET/MRI.

Authors:  Ali Afshar-Oromieh; Maya Wolf; Uwe Haberkorn; Marc Kachelrieß; Regula Gnirs; Klaus Kopka; Heinz-Peter Schlemmer; Martin T Freitag
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-05-15       Impact factor: 9.236

8.  The reconstruction algorithm used for [68Ga]PSMA-HBED-CC PET/CT reconstruction significantly influences the number of detected lymph node metastases and coeliac ganglia.

Authors:  Thomas Krohn; Anita Birmes; Oliver H Winz; Natascha I Drude; Felix M Mottaghy; Florian F Behrendt; Frederik A Verburg
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-11-29       Impact factor: 9.236

Review 9.  Lymphotropic nanoparticle-enhanced MRI in prostate cancer: value and therapeutic potential.

Authors:  Ansje S Fortuin; Robert Jan Smeenk; Hanneke J M Meijer; Alfred J Witjes; Jelle O Barentsz
Journal:  Curr Urol Rep       Date:  2014-03       Impact factor: 3.092

10.  68Ga-PSMA-11 PET/CT in prostate cancer patients with biochemical recurrence after radical prostatectomy and PSA <0.5 ng/ml. Efficacy and impact on treatment strategy.

Authors:  Andrea Farolfi; Francesco Ceci; Paolo Castellucci; Tiziano Graziani; Giambattista Siepe; Alessandro Lambertini; Riccardo Schiavina; Filippo Lodi; Alessio G Morganti; Stefano Fanti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-06-15       Impact factor: 9.236
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.